Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Alterity Therapeutics Limited (ATHE) provides access to the company’s disclosures as a foreign private issuer listed on NASDAQ. Alterity files reports under the Securities Exchange Act of 1934, including its annual report on Form 20‑F and current reports on Form 6‑K, and describes itself in these documents as a development stage enterprise focused on neurodegenerative diseases.
For investors following this clinical stage biotechnology company, Form 6‑K filings are particularly important. They often include material that has been released to the Australian Securities Exchange, such as quarterly Appendix 4C cash flow reports, clinical trial updates for ATH434 in Multiple System Atrophy (MSA), regulatory designations like U.S. FDA Fast Track status, and information on capital raisings or strategic placements. Other 6‑K submissions may contain meeting results, presentations to shareholders, and notices related to board or director changes.
Alterity’s Form 20‑F annual report (when filed) typically consolidates information on its business overview, risk factors, research and development focus on Parkinsonian and other neurodegenerative disorders, and its status as a clinical stage company. These filings complement the company’s scientific and clinical communications by outlining its segment focus on research and development and its listing arrangements on the Australian Securities Exchange and NASDAQ.
On Stock Titan, this page surfaces Alterity’s SEC filings as they are made available from EDGAR and pairs them with AI‑powered summaries to help readers interpret technical language. Users can quickly see the purpose of each 6‑K or 20‑F, identify items related to ATH434 clinical data, regulatory interactions, cash flow disclosures, and corporate governance, and then drill into the full text for detailed review.
Alterity Therapeutics (ATHE) is a development‑stage biopharmaceutical group focused on neurodegenerative diseases, notably ATH434 for Multiple System Atrophy (MSA). The company reported a net loss of A$12.15 million for the year and recorded a A$5.44 million R&D tax incentive as other income. Cash and cash equivalents increased to A$33.16 million at June 30, 2025, supported by significant equity raises including a placement of 3.636 billion shares at A$0.011 and issuance of 1.222 billion listed long‑dated options. Multiple patents (including composition of matter for ATH434) have been granted in several jurisdictions; one U.S. patent lists expiry June 7, 2026. Clinical and conference activity in 2024–2025 includes Phase 2 ATH434 data presented at major neurology meetings. The company continues to disclose material risks: ongoing operating losses, need for further financing, clinical development and manufacturing risks, intellectual property challenges, and NASDAQ listing and PFIC considerations.